Core Insights - RxSight, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a significant drop in stock price and revised revenue guidance [2][3]. Financial Performance - For Q2 2025, RxSight reported expected revenue of $33.6 million, which is a decrease of 4% year-over-year and a decrease of 11% compared to Q1 2025 [3]. - The company revised its 2025 revenue guidance, lowering the midpoint from $167.5 million to $125 million [3]. Market Reaction - Following the announcements regarding financial results and guidance, RxSight's stock price fell by $4.84 per share, or 37.84%, closing at $7.95 per share on July 9, 2025 [3]. Analyst Actions - Wells Fargo and BTIG downgraded RxSight's stock, citing "structural issues" and a challenging competitive environment [3].

SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating RxSight, Inc. (NASDAQ: RXST) to determine whether certain RxSight, Inc. officers and directors violated securities laws and breached fiduciary duties to shareholders. RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. What Now: If you own shar ...

ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) complied with federal securities laws. On July 8, 2025, RxSight announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance, revealing declines in revenue, Light Delivery Devices sales, and usage of Light Adjustable Lenses. Following this news, the price of the Company’s stock dropped.  If you purchased RxSight s ...

Core Viewpoint - Johnson Fistel, PLLP is investigating RxSight, Inc. for potential violations of federal securities laws related to misleading statements and undisclosed material information to investors [1][3]. Company Overview - RxSight, Inc. is facing scrutiny regarding its business outlook and product adoption trends, particularly after reporting significant declines in Light Delivery Device (LDD) sales and total revenue for Q2 2025 [3]. Financial Performance - On July 9, 2025, RxSight released preliminary financial results indicating notable declines in LDD sales and usage of its light adjustable intraocular lenses (LALs) [3]. - The company revised its full-year 2025 revenue guidance downward by approximately $42.5 million at the midpoint, attributing this to "adoption challenges over the last few quarters" [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether RxSight misled investors about its financial performance and future prospects [3]. - Investors who purchased RxSight securities and incurred losses may be eligible to participate in the investigation [2]. Whistleblower Information - Individuals with nonpublic information about RxSight are encouraged to assist with the investigation or explore options under the SEC Whistleblower Program, which may offer rewards of up to 30% of any successful enforcement action [4]. Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities fraud, with a strong track record in securing recoveries for clients [5][6].

Market Performance - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Wednesday, while the Dow rose 0.18% to 44,319.31, the NASDAQ increased 0.62% to 20,545.29, and the S&P 500 climbed 0.31% to 6,245.11 [1] - Communication services shares increased by 1.1%, while consumer staples stocks dipped by 1% [1] Commodity News - Oil prices rose by 0.6% to $68.74, while gold prices fell by 0.1% to $3,315.70. Silver decreased by 0.4% to $36.610, and copper dropped by 3.8% to $5.4715 [5] European Market - European shares showed positive performance, with the eurozone's STOXX 600 rising 0.71%, Spain's IBEX 35 Index increasing by 1.07%, London's FTSE 100 gaining 0.13%, Germany's DAX 40 up by 1.32%, and France's CAC 40 rising by 1.40% [6] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei gaining 0.33%, while Hong Kong's Hang Seng fell by 1.06%, China's Shanghai Composite declined by 0.13%, and India's BSE Sensex decreased by 0.21% [7] Company Developments - Calidi Biotherapeutics, Inc. saw its shares surge by 353% to $1.48 due to advancements in cancer treatment [9] - SU Group Holdings Limited's shares increased by 155% to $1.1609 after securing an HK$88.5 million hospital contract [9] - Evoke Pharma, Inc. shares rose by 171% to $7.20 following a notice of allowance for a U.S. patent application [9] - Bitmine Immersion Technologies, Inc. shares dropped by 47% to $59.22 after filing for a mixed shelf [9] - RxSight, Inc. shares fell by 42% to $7.39 after revising its 2025 revenue guidance downwards [9] - Vertical Aerospace Ltd. shares decreased by 31% to $4.77 after announcing a $60 million public offering at $5/share [9] Inventory Data - U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May, aligning with preliminary estimates [11] - U.S. crude oil inventories increased by 7.070 million barrels in the week ended July 4, marking the largest gain since January [11]

RxSight (RXST) Update / Briefing July 08, 2025 05:00 PM ET Speaker0Thank you for standing by. My name is Eric, and I will be your conference operator today. At this time, I would like to welcome everyone to the RxSight Q2 Preannounced Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.I would now like to turn the call over to Oliver Muravchowicz, Vice President of Investor Relations. Please go ahead.Spea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (Commission File Number) (IRS Employer Identification No.) 100 Columbia Aliso Viejo, California 92656 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Numbe ...

Core Viewpoint - RxSight, Inc. has announced preliminary financial results for Q2 2025, indicating a decrease in revenue and a revised full-year guidance, while also focusing on enhancing customer success and engagement with clinical partners [1][3]. Preliminary Second Quarter 2025 Results - Preliminary revenue for Q2 2025 is expected to be approximately $33.6 million, a decrease of 4% year-over-year and an 11% decrease compared to Q1 2025 [8]. - The company sold 27,380 Light Adjustable Lenses (LAL®/LAL+®), reflecting a 1% decrease in procedure volume from Q1 2025 but a 13% increase from Q2 2024 [8]. - The sale of 40 Light Delivery Devices (LDD™s) saw a significant decline, with a 45% decrease compared to Q1 2025 and a 49% decrease compared to Q2 2024 [8]. - As of June 30, 2025, the installed base of LDDs increased to 1,084, a 34% growth from 810 LDDs at the end of Q2 2024 [8]. Revised 2025 Guidance - Full-year revenue guidance has been revised downward to a range of $120.0 million to $130.0 million, a decrease from the previous range of $160.0 million to $175.0 million, implying a decrease of 14% to 7% compared to 2024 [9]. - Gross margin guidance has been increased to a range of 72% to 74%, up from the previous range of 71% to 73%, representing an increase of 130 to 330 basis points compared to 2024 [9]. - Operating expense guidance is set between $145.0 million and $155.0 million, indicating an increase of 7% to 14% compared to 2024, which includes non-cash stock-based compensation expenses estimated between $27.0 million and $30.0 million [9].

Core Insights - Investors in the Medical - Instruments sector may consider Fresenius (FMS) or RxSight, Inc. (RXST) as potential undervalued stocks [1] Valuation Metrics - Fresenius has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while RxSight, Inc. has a Zacks Rank of 4 (Sell) [3] - FMS has a forward P/E ratio of 12.19, significantly lower than RXST's forward P/E of 2,025.00, suggesting FMS is more attractively priced [5] - The PEG ratio for FMS is 1.09, while RXST's PEG ratio is 53.43, indicating FMS has a better growth outlook relative to its valuation [5] - FMS has a P/B ratio of 0.97, compared to RXST's P/B of 1.96, further supporting FMS as the more undervalued option [6] - Based on these valuation metrics, FMS holds a Value grade of B, while RXST has a Value grade of F, reinforcing FMS as the superior value option [6]

RxSight LAL Technology & Benefits - The Light Adjustable Lens (LAL) is the only customizable IOL for optimized vision without glasses[11] - LAL eyes have better odds of achieving optimal visual outcomes (absolute MRSE and MRCyl ≤ 050 D)[15] - 92% of surveyed customers believe LAL provides the highest quality of vision[25] - Over 90% of patients achieved 20/25 distance and J2 near vision without glasses in real-world data from over 3,000 eyes[25] - In an RxSight customer survey, 40% of LAL patients would have received a non-premium IOL[26] Market & Financial Performance - Approximately 32 million global cataract procedures are performed annually, including about 5 million in the U.S[9] - The global premium IOL market sees approximately 5 million procedures annually, including about 1 million in the U S[10] - Average additional practice net revenue per LAL implanted is $2,064[27,28] - RxSight's total revenue in Q1 2025 reached $34 million, a 36% growth compared to Q1 2024[30] - The LDD installed base grew by 43% compared to Q1 2024[30] Future Growth & Expansion - US Premium Cataract Surgery is expected to grow from 20% to approximately 35% of overall cataract procedures[32] - Key OUS markets make up >80% of global procedures with growing procedure potential[39]